Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis.
Lin JF, Hu PS, Wang YY, Tan YT, Yu K, Liao K, Wu QN, Li T, Meng Q, Lin JZ, Liu ZX, Pu HY, Ju HQ, Xu RH, Qiu MZ. · 2022
Read Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. by Lin JF, Hu PS, Wang YY, Tan YT, Yu K, Liao K, Wu QN, Li T, Meng Q, Lin JZ, Liu ZX, Pu HY, Ju HQ, Xu RH, Qiu MZ. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8882671.txt.
Introduction
Lin and co-authors uncover why some colorectal cancers shrug off oxaliplatin chemotherapy. The drug works partly through oxidative stress. A metabolic enzyme, NFS1, builds iron-sulfur clusters for the cell. Its role in drug sensitivity was unknown. The team screened metabolic genes with a CRISPR library in living tumors. Losing NFS1 made cancer cells far more sensitive. Cell and animal tests confirmed the effect.
Without NFS1, oxaliplatin triggered PANoptosis, a blended death program. Reactive oxygen species rose inside the cells. The drug also raised phosphorylation on NFS1 itself. That change, at one serine site, blocked the death program. Tumors with high NFS1 fared worse in patients. They also answered chemotherapy poorly. The authors propose blocking NFS1 to sharpen platinum therapy.
Catalog record
| CREATOR | Lin JF, Hu PS, Wang YY, Tan YT, Yu K, Liao K, Wu QN, Li T, Meng Q, Lin JZ, Liu ZX, Pu HY, Ju HQ, Xu RH, Qiu MZ. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis By Jin-Fei Lin, Pei-Shan Hu, Yi-Yu Wang, Yue-Tao Tan, Kai Yu, Kun Liao, Qi-Nian Wu, Ting Li, Qi Meng, Jun-Zhong Lin, Ze-Xian Liu, Heng-Ying Pu Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-022-00889-0 ABSTRACT Metabolic enzymes have an indispensable role in metabolic reprogramming, and their aberrant expression or activity has been associated with chemosensitivity. Hence, targeting metabolic enzymes remains an attractive approach for treating tumors. However, the influence and regulation of cysteine desulfurase (NFS1), a rate-limiting enzyme in iron–sulfur (Fe–S) cluster biogenesis, in colorectal cancer (CRC) remain elusive. Here, using an in vivo metabolic enzyme gene-based clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 library screen, we revealed that loss of NFS1 significantly enhanced the sensitivity of CRC cells to oxaliplatin. In vitro and in vivo results showed that NFS1 deficiency synergizing with oxaliplatin triggered PANoptosis (apoptosis, necroptosis, pyroptosis, and ferroptosis) by increasing the intracellular levels of reactive oxygen species (ROS). Furthermore, oxaliplatin-based oxidative stress enhanced the phosphorylation level of serine residues of NFS1, which prevented PANoptosis in an S293 phosphorylation-dependent manner during oxaliplatin treatment. In addition, high expression of NFS1, transcriptionally regulated by MYC, was found in tumor tissues and was associated with poor survival and hyposensitivity to chemotherapy in patients with CRC. Overall, the findings of this study provided insights into the underlying mechanisms of NFS1 in oxaliplatin sensitivity and identified NFS1 inhibition as a promising strategy for improving the outcome of platinum-based chemotherapy in the treatment of CRC. INTRODUCTION Chemotherapy remains one of the main nonsurgical tumor control approaches in patients with unresectable colorectal cancer (CRC).1 However, associated side effects and chemosensitivity are the main contributors to treatment failure.2 Therefore, the development of effective strategies for enhancing chemosensitivity is urgently needed to improve the survival and prognosis of patients with CRC. Cells carry out multiple regulated cell death programs, via extensive crosstalk that can be activated simultaneously under specific conditions. This fact is consistent with the recently proposed concept of “PANoptosis”.3 Interferon regulatory factor 1 (IRF1), TNF-α, and IFN-γ have been shown to induce PANoptosis to prevent tumorigenesis, particularly in CRC colitis-associated tumorigenesis.4,5 However, the role of PANoptosis in tumor chemosensitivity has not been elucidated. Metabolic reprogramming is a crucial hallmark of malignant cells.6,7 Tumors develop fixed dependencies to reprogram metabolic activities, which can be exploited for the diagnosis, monitoring, and treatment of tumors.8,9 An increasing number of studies indicate that several inhibitors targeting these metabolic pathways exhibit effectiveness in tumor suppression, and these strategies have thus advanced into clinical trials.10 Considering that metabolic enzymes have an indispensable role in metabolic reprogramming and their aberrant expression or activity are closely related to tumorigenesis, tumor progression, and chemosensitivity,10,11 therefore, targeting and inhibiting these metabolic enzymes could significantly increase the chemosensitivity of tumor cells. Iron–sulfur (Fe–S) clusters are essential cofactors of Fe–S proteins, which are involved in a multitude of cellular processes, including iron homeostasis, energy metabolism, and lipid biosynthesis.12,13 Defects in Fe–S cluster biogenesis can cause metabolic diseases and even affect the tumorigenesis and development of tumors in humans.14,15 During periods of rapid cancer cell growth, increased Fe–S cluster turnover increases Fe–S cluster biosynthesis to replenish Fe–S cluster storage, especially under external stimuli, such as redox stress.16 However, the role and mechanism of Fe–S cluster metabolism in tumor chemosensitivity is not fully understood, and further research is needed. In this study, using an in vivo metabolic enzyme gene-based CRISPR-Cas9 screen, we revealed that cysteine desulfurase (NFS1) deficiency synergizing with oxaliplatin treatment triggered PANoptosis by increasing intracellular oxidative stress. NFS1 prevented PANoptosis in an S293 phosphorylation-dependent manner under oxaliplatin treatment. We also demonstrated that NFS1 was transcriptionally regulated by MYC and that high NFS1 expression in patients with CRC was associated with a poor prognosis. Overall, our study revealed NFS1 inhibition as an actionable strategy for improving the antitumor efficacy of platinum-based chemotherapy in CRC treatment. RESULTS In vivo CRISPR screening reveals that NFS1 deficiency enhances the sensitivity of CRC cells to oxaliplatin To identify cell-intrinsic metabolic enzymes that synergize with chemotherapy in CRC, we performed a metabolic enzyme gene-based CRISPR-Cas9 screen of transplantable tumors treated with control or oxaliplatin, which is the backbone agent for patients with CRC in both adjuvant and metastatic settings17,18 (Fig. 1a and Supplementary Fig. S1a, b). Compared with the control, we showed the depleted and enriched genes in the oxaliplatin-treatment group in Fig. 1b. An inspection of the depleted genes revealed that their loss increased the sensitivity of tumor cells to oxaliplatin-based chemotherapy (Supplementary Fig. S1c). Of note, NFS1 and ferredoxin-2 (FDX2/FDX1L) were among the most depleted genes in the oxaliplatin-treatment group (Fig. 1c, Supplementary Fig. S1d, and Supplementary Table S5). As NFS1 and FDX2 are two essential metabolic enzymes in Fe–S cluster biosynthesis whereby NFS1 harvests sulfur from cysteine residues and FDX2 transfers electrons for the initial step19 (Fig. 1d), which suggests that NFS1 and FDX2 could induce oxaliplatin resistance in CRC.Fig. 1In vivo CRISPR screening reveals that NFS1 deficiency enhances the sensitivity of CRC cells to oxaliplatin (Oxa). a Diagram showing the strategy of the CRISPR-based screen in vivo (n = 6). b Volcano plot illustrating the depleted or enriched genes in the oxaliplatin-treatment group compared with the control group based on the depletion or enrichment of sgRNAs. Each dot represents a gene whose knockout can enhance (blue) or reduce (red) the sensitivity of cells to oxaliplatin treatment. c Illustration of the top ten candidates depleted in the oxaliplatin-treatment group. The analyzed CRISPR screening data are provided in Supplementary Table S5. d Schematic illustration of Fe–S cluster biogenesis and the main enzymes involved in this process. e MTS analysis of the proliferation of HCT116 cells in which NFS1 or FDX2 is silenced. f Quantification of colony formation analysis reflecting the proliferation of control and NFS1-knockdown HCT116 and DLD1 cells. g, h Cell viability of HCT116 and DLD1 cells treated with different concentrations of oxaliplatin for 48 h after NFS1 knockdown. i, j LDH analysis indicating the cytotoxicity of different concentrations of oxaliplatin for 48 h in HCT116 and DLD1 cells with NFS1 knockdown. k Live/dead viability/cytotoxicity assay showing the dead (red) and live (green) cells among control and NFS1-knockdown HCT116 cells treated with 40 µM oxaliplatin for 24 h. Scale bar = 100 μm. l Quantification of the relative number of dead cells in (k). m, n Cell viability (m) and cytotoxicity (n) assessments of control and NFS1-knockdown HCT116 cells treated or not treated with 40 µM oxaliplatin for 24 h in combination with the apoptosis inhibitor Z-VAD-FMK (VAD, 25 µM), the necroptosis inhibitor necrostatin (Nec, 20 µM), the ferroptosis inhibitor ferrostatin-1 (Fer, 10 µM), the pyroptosis inhibitors Ac-DMPD/DMLD-CMK (DMPD/DMLD, 20 µM) and disulfiram (dis, 1 µM) or the autophagy inhibitor 3-methyladenine (3-me, 10 µM). The data in (e–j) and (l–n) are representative of three independent experiments and presented as the mean ± SD. The P values in (e–h) were calculated by two-way ANOVA with Dunnett’s multiple comparisons test, those in (l–n) were calculated by one-way ANOVA with Tukey’s multiple comparisons test, and those in (i, j) were calculated by two-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001 To evaluate the function of NFS1